Department of Oncology, NanFang Hospital, 198153Southern Medical University, Guangzhou, China.
Department of Thoracic Surgery, NanFang Hospital, 198153Southern Medical University, Guangzhou, China.
Int J Biol Markers. 2022 Jun;37(2):170-177. doi: 10.1177/03936155221088882. Epub 2022 Apr 11.
To explore the relationship between breast cancer susceptibility gene 1 (BRCA1) expression and the prognostic value of platinum-based chemotherapy for stage II-IV non-small cell lung cancer (NSCLC).
PubMed, Web of Science, Embase, and Cochrane Library were searched from inception to August 2021, for retrieving literature related to BRCA1 expression and prognostic value of platinum-based chemotherapy in NSCLC patients. Stata 15.0 was employed for statistical analysis.
A total of 15 articles were included. Compared with the low BRCA1 expression, its high expression negatively affected the overall survival of NSCLC patients treated with platinum-based chemotherapy (hazard ratio (HR) = 1.53, 95% confidence interval (CI): 1.01-2.31, < 0.05). No significant difference was identified in the effect of both low and high BRCA1 expression on event-free survival (HR = 1.73, 95% CI: 0.98-3.05, > 0.05). Subgroup analysis showed that significant differences existed in overall survival and event-free survival in Caucasian population; that is, compared with low BRCA1 expression, its high expression negatively affected the overall survival (HR = 1.79, 95% CI: 1.15-2.79, < 0.05) and event-free survival (HR = 2.39, 95% CI: 1.43-3.97, < 0.05). Nevertheless, there were no significant differences in overall survival and event-free survival in China.
BRCA1 expression is correlated with the prognostic value of platinum-based chemotherapy for stage II-IV NSCLC patients. In Caucasian population, compared with low BRCA1 expression, its high expression has a negative effect on the overall survival and event-free survival in stage II-IV NSCLC patients after platinum-based chemotherapy; however, this correlation was not found in China.
探讨乳腺癌易感基因 1（BRCA1）表达与铂类化疗对 II-IV 期非小细胞肺癌（NSCLC）患者预后价值的关系。
检索 PubMed、Web of Science、Embase 和 Cochrane Library 从建库至 2021 年 8 月的相关文献，评估 BRCA1 表达与 NSCLC 患者铂类化疗疗效及预后的关系。采用 Stata 15.0 软件进行统计学分析。
共纳入 15 篇文献。与 BRCA1 低表达相比，高表达与铂类化疗的 NSCLC 患者总生存（HR=1.53，95%CI：1.01-2.31，P<0.05）负相关。BRCA1 低表达和高表达对无事件生存的影响无统计学差异（HR=1.73，95%CI：0.98-3.05，P>0.05）。亚组分析显示，在白种人群中，总生存和无事件生存存在显著差异，即与 BRCA1 低表达相比，高表达与总生存（HR=1.79，95%CI：1.15-2.79，P<0.05）和无事件生存（HR=2.39，95%CI：1.43-3.97，P<0.05）负相关。但在中国人群中，BRCA1 表达与总生存和无事件生存无相关性。
BRCA1 表达与 II-IV 期 NSCLC 患者铂类化疗的预后价值相关。在白种人群中，与 BRCA1 低表达相比，高表达与铂类化疗后 II-IV 期 NSCLC 患者的总生存和无事件生存负相关；但在中国人群中未发现这种相关性。
